Sign in
Taking people in SpainPhase 1

Adding RUTI® to BCG treatment for high-risk early-stage bladder cancer

Tests whether adding RUTI® to BCG is safe in adults with early-stage bladder cancer.

Key facts

Who runs it
Laboratorio Reig Jofre S.A.
Where
Badalona and L'hospitalet De Llobregat, SpainSee the 2 sites
Registry title
A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.
Status
Recruiting
Phase
Phase 1
People taking part
44 people, planned
Started
17 Jul 2026
Expected to end
30 Jun 2028
Type of study
Interventional
Record updated
18 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with high-risk early-stage bladder cancer that has not grown into the muscle. People get standard BCG treatment plus either RUTI® or a look-alike treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
High-risk non-muscle invasive bladder cancer (NMIBC)

Where in Spain

  • Hospital Germans Trias i PujolBadalona, SpainTaking people
  • Bellvitge University HospitalL'hospitalet De Llobregat, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Adding RUTI® to BCG treatment for high-risk early-stage bladder cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
18 June 2026